文献速递脑血管病外科神经重症

右美托咪定与接受手术的蛛网膜下腔出血患者院内死亡风险降低相关

Dexmedetomidine is Associated with Reduced In-Hospital Mortality Risk of Patients with Subarachnoid Hemorrhage Undergoing Surgery.
PubMed 文献 · World Neurosurg · 2024-12-23

本研究基于MIMIC-IV数据库分析527例蛛网膜下腔出血患者,比较不同镇静药物与院内死亡率的关系。与丙泊酚和咪达唑仑相比,使用右美托咪定与院内死亡率降低显著相关(OR 0.369,95%CI 0.237-0.574,P<0.001),调整混杂因素后关联仍存在,且肌酐在其中起中介作用。

要点

  • 与丙泊酚和咪达唑仑相比,右美托咪定与蛛网膜下腔出血患者院内死亡率降低相关(OR 0.369,95%CI 0.237-0.574,P<0.001)。
  • 调整人口学、合并症和实验室检查等变量后,右美托咪定仍与较低的院内死亡率相关。
  • 肌酐在右美托咪定与院内死亡率的关系中起中介作用。

核心结论

  • 右美托咪定与蛛网膜下腔出血患者院内死亡率显著降低相关,提示镇静药物选择对患者结局的重要性,右美托咪定可能改善患者预后。

研究设计与样本

  • 基于MIMIC-IV数据库的分析,共纳入527例患者,其中男性301例,主要结局为院内死亡率。

主要发现

  • 与丙泊酚和咪达唑仑相比,使用右美托咪定与院内死亡率降低显著相关(OR 0.369,95%CI 0.237-0.574,P<0.001)。
  • 调整人口学、合并症和实验室检查等变量后,右美托咪定仍与较低的院内死亡率相关。
  • 无论是否存在脑血管疾病,使用右美托咪定均与院内死亡风险降低相关。
  • 肌酐在右美托咪定对院内死亡率的保护作用中起中介作用。

关键数值与推荐

  • 与丙泊酚和咪达唑仑相比,右美托咪定与院内死亡率降低相关(OR 0.369,95%CI 0.237-0.574,P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Subarachnoid hemorrhage (SAH) is a severe neurologic event with high mortality. The choice of sedatives in SAH management may influence patient outcomes. This study aimed to investigate the association between sedatives and in-hospital mortality among patients with SAH. METHODS: This study analyzed data from the MIMIC-IV database, and in-hospital mortality was the primary outcome. Key variables collected included sedatives, demographics, comorbidities, vital signs, laboratory tests, and severity scores. Univariate and multivariate logistic regression analyses were used to assess associations between sedative use and in-hospital mortality, with adjustments for confounding factors. Further stratified analyses explored the effects of dexmedetomidine across different patient subgroups, and mediation analysis evaluated the role of creatinine in the relationship between dexmedetomidine and mortality. RESULTS: A total of 527 patients were included in this study, with 301 males. Compared with propofol and midazolam, the use of dexmedetomidine was significantly related to the reduction of in-hospital mortality in patients with SAH (odds ratio, 0.369; 95% confidence interval, 0.237-0.574; P < 0.001). After adjusting for variables such as demographics, comorbidities, and laboratory tests, dexmedetomidine remained associated with lower in-hospital mortality. In addition, our findings indicated that dexmedetomidine use was associated with a reduced risk of in-hospital mortality regardless of the presence of cerebrovascular disease. We discovered that creatinine acted as a mediator in the protective effect of dexmedetomidine on in-hospital mortality. CONCLUSIONS: Dexmedetomidine is associated with significantly lower in-hospital mortality in patients with SAH. These findings underscore the importance of sedative choice for patients with SAH, suggesting that dexmedetomidine could enhance patient outcomes.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Liu Y, Peng J, Zhang YH, et al. Dexmedetomidine is Associated with Reduced In-Hospital Mortality Risk of Patients with Subarachnoid Hemorrhage Undergoing Surgery. World Neurosurg. 2024. PMID: 39645076. doi:10.1016/j.wneu.2024.11.122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。